Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

The purpose of this study is to assess safety and efficacy of weekly epoetin alfa (Hemax® ) administered for 12 weeks in patients with non curable solid tumors or lymphoma with anemia (hemoglobin < 10g/dl) undergoing palliative care chemotherapy.

Further Study Information

Patients with non curable solid tumors or lymphoma with anemia (hemoglobin < 10g/dl) undergoing palliative care chemotherapy will enter this 12 week single arm open label study. Epoetin alfa 40.000-60.000 IU/week will be administered subcutaneously and controlled every 2 weeks. Up or down titration will be performed according to the currently approved prescription guidance for a total of 12 weeks of treatment. Study end points will be assessed every 4 weeks until final 12 week visit.

Eligibility Criteria

Inclusion Criteria:

• Confirmed diagnosis of non curable cancer or lymphoma

• Receiving a palliative chemotherapy regimen

• Hemoglobin < 10.0 g/dL

• Performance ≤ 3 of Eastern Cooperative Oncology Group (ECOG) performance status

• Life expectancy of ≥ 3 months

• Postmenopausal o premenopausal women receiving effective contraceptive method

Exclusion Criteria:

• Active bleeding that may have caused anemia in the prior 30 days.

• Uncontrolled hypertension

• Anemia for another cause other than cancer or chemotherapy

• Untreated iron or folic acid deficiency

• Transfusion in the last 30 days prior to baseline visit

• Treatment with an erythropoiesis stimulating agent 3 months prior to the baseline visit

• Increased risk of thromboembolic disease

• Radiotherapy in pelvis or spine in the last 60 days

• Myelodysplasic syndrome

• History of congestive heart failure

• Pregnant or lactating

• Patient with known allergy to human albumin or related products

Trial Contact Information

Trial Lead Organizations/Sponsors

Bio Sidus SA

Roberto Diez, MD

Study Director

Roberto Diez, MD		Ph: 5411-4909-8049
		Email: r.diez@biosidus.com.ar

Argentina
	Buenos Aires
	Centro de Medicina Integral e Investigación Clínica
		Carlos Guzman Machado, MD
Buenos Aires
	Berazategui
	Centro Oncologico de Investigaciones Buenos Aires
		Mirta Varela, MD
	Lanus Este
	Hospital Zonal Especializado en Oncologia de Lanus
		Eduardo Diez, MD	Ph: 5411-4241-2968
			Email: terapeutica.lanus@yahoo.com.ar

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01374373
Information obtained from ClinicalTrials.gov on December 16, 2012

Back to Top